Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has signed an agreement under which Ventana Medical Systems Inc., a member of the Roche Group, will acquire 100 percent of BioImagene, Inc., a privately held company based in Sunnyvale, California.
Published News
GlaxoSmithKline confirmed that the company has commenced the Phase III clinical trials programme of its candidate herpes zoster vaccine currently being developed for the prevention of shingles. The phase III clinical trials will study more than 30,000 patients globally and will evaluate the efficacy, safety and immunogenicity of the candidate vaccine.
The World Health Organization (WHO) has granted prequalification to Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed])for active immunization of infants and children from 6 weeks through five years of age against invasive disease, pneumonia and otitis media caused by the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) contained in t
Merck announced the Merck Company Foundation and the Bill & Melinda Gates Foundation are committing an additional $60 million to support Botswana's African Comprehensive HIV/AIDS Partnerships (ACHAP). Merck is known as MSD outside the US and Canada.
The Novartis 2010 Immunology Prizes were presented at the 16th International Congress of Immunology in Kobe, Japan. Since 1992, the Novartis Prizes for Immunology have been awarded every third year for outstanding contributions to basic and clinical immunology.
GSK European Commission amends licence for Cervarix®
Posted by PharmaNewsEU 6 days ago (http://www.pharmanews.eu)
GlaxoSmithKline (GSK) confirmed that the European Commission has granted Marketing Authorisation to amend the licence for its cervical cancer vaccine, Cervarix®. The approval from the European Commission is important as it recognises the extent of cervical cancer protection demonstrated by Cervarix®, which was not highlighted by the previous indication.
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2
Shire Announces European Approval of VPRIV® (velaglucerase alfa)
Posted by PharmaNewsEU 6 days ago (http://www.pharmanews.eu)
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that the European Commission has granted marketing authorisation for VPRIV® (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease. VPRIV has been authorized as an orphan medicine through the Centralised Procedure, mak
Change in environment sparks stem cell cross-over
Posted by PharmaNewsEU 6 days ago (http://www.pharmanews.eu)
EU-funded scientists have discovered that stem cells from one of the immune system's main organs can be reprogrammed to form hair follicle stem cells. The key lies in altering the environment in which the cells are grown. These results demonstrate that it is possible to alter stem cells without genetic manipulation. Details of the study are published in Nature. Ectoderm, endoderm and mesoderm are
Lead Wire Extraction Surgery Might Be More Hazardous Than Once Thought, Including Serious Cardiovascular Injuries And Deaths
Sort News
abbott
actavis
aids
alli
amgen
aranesp
astrazeneca
avandia
baxter
bayer
biotech
boehringer ingelheim
bristol-myers squibb
byetta
cancer
china
clinical
clinical trials
clothing
cnto411
conference
crestor
diabetes
digitek
drug
drug discovery
drug-injury
drug-safety
drugs
ec
electronic cigarette liquid
eli lilly
emarketing
emea
eu
eyeforpharma
fda
femur-fracture
fosamax
generic
generics
genzyme
glaxosmithkline
gsk
h1n1
health
health 2.0
heparin
industry leaders
insulin
intelligence
jacob fleming
jacob fleming group
januvia
jarvik
johnson & johnson
law
legal
lilly
lipitor
liver-failure
loans
lundbeck
manhattan research
medication-errors
merck
merck kgaa
nexavar
novartis
novo nordisk
nplate
nycomed
onj
pancreatitis
pfizer
pharma
pharmalot
preemption
raptiva
recall
research
roche
sandoz
sanofi-aventis
schering-plough
seroquel
shire
sprint-fidelis
summit
takeda
teva
training courses
transinsight
trasylol
vytorin
who
wyeth
yasmin
yaz
zetia